Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Isomorphic Lab’s proprietary drug-discovery model is a major advance, but scientists developing open-source tools are left ...

AI could review data sets to assist clinical scientists ...

"Dosing the first patient in Phase III represents a major milestone for MDR-001 and for AI-enabled drug development," said Zhangming Niu, Founder and Chief Executive Officer of MindRank. "We believe ...

AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...

CLEVELAND, OHIO, OH, UNITED STATES, February 24, 2026 /EINPresswire.com/ -- The Bommer Group, a life sciences-focused ...

Merck and Mayo Clinic are partnering to use AI technology and large-scale clinical data to speed drug development in MS and other conditions.

Mayo Clinic, for its part, described the collaboration as its first strategic partnership of this scale with a global ...

Explore the impact of AI in drug discovery as 2026 promises critical clinical results and industry transformations.

Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform that integrates the wisdom of traditional ...

Explore the latest advancements in Alzheimer’s drug research, revealing hope for earlier diagnosis and new treatment options.